Printer Friendly

Articles from M2 Pharma (June 13, 2019)

1-20 out of 20 article(s)
Title Author Type Words
Aimmune Therapeutics Discusses AR101's Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting. 663
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease. 329
Akrevia Therapeutics names new Chief Operating Officer. 123
Antiviral Compounds Developer ReViral Names Sapir as Chief Executive Officer. 612
Biocorp's Mallya device receives CE IIb approval. 197
Boehringer Ingelheim extends collaboration with University of Dundee. 154
Boehringer Ingelheim, University of Dundee Extend Ongoing Anti-Cancer Alliance. 331
Bolder BioTechnology wins FDA's ODD for BBT-059 for treating ARS. 213
Deciphera Pharmaceuticals, Zai Lab Ink Exclusive License Agreement for Ripretinib in Greater China. 539
eMurmur passes CE mark certification for its heart murmur detection eMurmur ID solution. 280
FDA Approves Two New Indications for US Merck's Keytruda. 460
InGeneron Extends Series D Financing to USD 43m to Bring Regenerative Cell Therapy into the Clinic. 457
Ionis Pharmaceuticals names new President and CEO of Herman and Associates. 225
Kerecis concludes USD16m Series C funding with investors. 184
Nitrome Biosciences secures Michael J. Fox Foundation Target Advancement grant. 175
Novartis' Cosentyx achieves endpoints in psoriatic arthritis study. Clinical report 108
Sirion Biotech Licenses Technology to National Institute of Allergy and Infectious Diseases to Boost Clinical Efficacy of Lentivector Gene Therapy for X-Linked SCID. 528
SpeeDx Receives FDA Breakthrough Designation for ResistancePlusGC. 449
USFDA approves Merck's anti-PD-1 therapy Keytruda. 168
Viralym-M Granted Regenerative Medicine Advanced Therapy Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT. 691

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters